{"prompt": "['4', 'MC1488', 'Schema', 'Registration', 'Elderly, newly', 'Relapsed/Refractory AML', 'diagnosed AML', '& HMA failure MDS', 'Randomization', 'Arm A:', 'AZD1775 days 1-5 &', '8-12', 'Arm B;', 'Arm C:', 'AraC days 1-5 & 8-12', 'AZD1775 days 1-5 & 8-12', 'AZD1775 days 1-5, 8-', 'AraC days 1-5 & 8-12', '12, 15-19, 22-26', 'Disease progression', 'Unacceptable adverse events', 'Patient refusal', 'Event monitoring', 'per Section 18.0', 'If a patient is deemed ineligible or a cancel, please refer to Section 13.0 for follow-up information.', 'Cycle length=28 days', 'NOTE: The Safety portion of this trial will monitor six patients in each arm and observe them for a', 'minimum of 28 days to assess toxicities.', 'Generic name: AZD1775', 'Generic name: Cytosine arabinoside', 'Brand name(s): n/a', 'Brand name(s): Cytosar, R', 'Mayo Abbreviation: AZD1775', 'Mayo Abbreviation: AraC (Cytarabine)', 'Availability: Provided by AstraZeneca', 'Availability: Commercially available']['5', 'MC1488 WEE1', 'MCCC', '1.0', 'Background', '1.1', 'Acute Myeloid Leukemias (AML) and Myelodysplastic Syndrome (MDS)', 'Despite progress in the treatment of AML and MDS, most adult patients with AML and', 'advanced/progressive MDS still do very poorly with current therapy and many die from', 'their disease (Abe et al. 2008). Patients with primary refractory or relapsed AML have a', 'particularly poor outcome, as well as MDS patients who are refractory, progress on or', 'relapse after hypomethylating agents (HMA) based therapies (Duong et al. 2013, Pr\u00e9bet', 'et al. 2011, Jabbour et al. 2010).', 'Acute myeloid leukemia patients who fail to achieve a complete remission (CR) with first', 'induction therapy have a dismal outcome and only a small percentage of patients are alive', 'at 1 year (Bai et al 2008). Current therapy is also inadequate for relapsed leukemias with', 'a true long-term cure rate of less than 10% (Bai et al. 2008). Recently, comparable', 'clinical activity and outcomes between HMAs and cytotoxic chemotherapy has been', 'demonstrated in secondary, elderly and unfavorable cytogenetics AML in first line', 'therapy (Quantas-Cardama et al. 2012 and Fenaux et al. 2010). Thus, many experts feel', 'that these patients are candidates for lower intensity treatment as first line intervention.', 'The outcome of patients with advanced myelodysplastic syndrome (MDS) in the', 'intermediate and IPSS intermediate-2, and especially high-risk category is almost as poor', 'as for patients with acute leukemia. Median survival in this group is 4-5 months (Schanz', 'et al. 2012 and Greenberg et al. 1997). The two approved HMAs Azacytidine (AZA) and', 'Decitabine (DAC) have activity, however CR rates are less than <10-18% and overall', 'responses (CR, PR and clinical benefit such as hematological improvements) approach at', 'a', 'maximum 40-50% in the first line treatment setting in MDS (Fenaux et al 2009 and', 'Lubbert et al 2011).', 'Responses and survival in MDS patients having failed or progressed on or after HMA', 'treatment is very poor with a median survival of 4.3-5.8 months and a 1-year survival of', '17-29% in the largest three studies to date (Duong et al. 2013, Pr\u00e9bet et al. 2011, Jabbour', 'et al. 2010). Accordingly HMA failure MDS represents one of the largest patient groups', 'in need for novel agents and investigational therapies. In fact, apart from allogeneic', 'transplant for which most patients do not qualify, investigational regimens were as good', 'and better than cytotoxic chemotherapy after HMA failure (Pr\u00e9bet et al. 2011).', 'Azacitidine (AZA) and Decitabine (DAC) are often used as lower intensity, outpatient', 'treatments in elderly AML patients not fit for induction treatment. Responses are', 'comparable to somewhat lower than in treating MDS patients with CR/CRi rates ranging', 'from 7-18% (Fenaux et al. 2010 and Kantarjian et al. 2012). Thus, there is likewise a', 'great demand for improvement of alternative lower intensity, outpatient regimens and', 'new combinations for elderly AML patients. Interestingly, in several earlier studies low-', 'dose s.c. Cytarabine (AraC) alone or with growth factor support exhibited quite', 'encouraging response rates of CR and PR of 18% and 8% respectively (Aul & Schneider', '1989). Several studies also have been reported on the potential activity of low-dose AraC', '(AraC) in MDS (Visani et al. 2004). However, if the natural history of the disease is', 'changed, and there is significant room for improvements in therapeutic options for these', 'patients. In summary, available data demonstrates the clinical activity of HMAs and', 'AraC specifically in elderly AML and MDS patients, providing additional clinical']\n\n###\n\n", "completion": "END"}